Last reviewed · How we verify
Perforomist, nebulization, COPD
Perforomist, nebulization, COPD is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by Dey. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Formoterol fumarate.
Perforomist is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow in COPD patients.
Perforomist is a small molecule medication used for nebulization, specifically indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It contains the active ingredient formoterol, which is administered via inhalation solution.
At a glance
| Generic name | Perforomist, nebulization, COPD |
|---|---|
| Also known as | Formoterol fumarate |
| Sponsor | Dey |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
The drug activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained airway dilation. This provides long-acting bronchodilation (approximately 12 hours) that helps reduce airway obstruction and improve breathing in chronic obstructive pulmonary disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Formoterol in Diabetes (PHASE2)
- Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) (PHASE4)
- Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE3)
- Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography (PHASE4)
- Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (PHASE3)
- A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perforomist, nebulization, COPD CI brief — competitive landscape report
- Perforomist, nebulization, COPD updates RSS · CI watch RSS
- Dey portfolio CI
Frequently asked questions about Perforomist, nebulization, COPD
What is Perforomist, nebulization, COPD?
How does Perforomist, nebulization, COPD work?
What is Perforomist, nebulization, COPD used for?
Who makes Perforomist, nebulization, COPD?
Is Perforomist, nebulization, COPD also known as anything else?
What drug class is Perforomist, nebulization, COPD in?
What development phase is Perforomist, nebulization, COPD in?
What are the side effects of Perforomist, nebulization, COPD?
What does Perforomist, nebulization, COPD target?
Related
- Drug class: All Long-acting beta-2 agonist (LABA) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor
- Manufacturer: Dey — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Also known as: Formoterol fumarate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing